Background
Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 80% of pancreatic cancer cases, is one of the most malignant diseases world-wide. Surgical resection offers the best chance for a possible cure; however, because of the absence of specific symptoms and the lack of early detection, PDAC is usually diagnosed at an advanced stage. Thus, only 10–20% of diagnosed patients present with potentially resectable pancreatic cancer [
1,
2]. Chemotherapy also plays a critical role in improving symptoms and prolonging overall survival of PDAC patients. However, PDAC is highly resistant to chemotherapy, including gemcitabine treatment, which is generally regarded as the first-line chemotherapy regimen [
3]. In the past decades, despite constant efforts to improve the diagnosis and treatment of PDAC, this devastating disease still has a dismal prognosis [
4-
7]. The roadblocks to major progress are predominantly related to the sophisticated biology and regulatory mechanisms underlying this disease. Hence, a better understanding of the genetic alterations and molecular mechanisms involved in PDAC development and chemoresistance will facilitate the identification of novel diagnostic and therapeutic targets [
8].
Studies on human genomes have demonstrated that non-coding RNAs (ncRNAs), which do not encode proteins, account for more than 90% of the transcriptome [
9]. The functions of a number of ncRNAs have been characterized, and it is evident that they play crucial roles in the regulation of gene expression, splicing, epigenetic control, chromatin structure, and nuclear transport [
10-
14]. Among the various classes of ncRNAs, microRNAs (18–200 nucleotides) have been extensively studied, and it has been shown that >1000 microRNAs regulate up to 30% of all protein-encoding genes [
13-
16]. Additionally, long non-coding RNAs (lncRNAs), defined as non-coding RNAs more than 200 nucleotides in length, are gaining prominence because of their emerging roles in the regulation of critical cellular functions, including the modulation of apoptosis and proliferation, reprogramming of human-induced pluripotent stem cells, tissue differentiation, and as markers of cell fate [
17-
21]. Importantly, a number of cancer-specific lncRNAs have been identified, which may be employed as novel biomarkers for diagnosis and as therapy targets [
22,
23].
The HOTTIP lncRNA, located at the 5′ end of the
HOXA cluster, was recently functionally characterized [
24]. Consistent with its genomic position, HOTTIP was significantly expressed in anatomically distal human fibroblasts [
24]. The activity of HOTTIP is a result of its interaction with the WDR5/MLL complex, which enhances histone H3 lysine 4 trimethylation to activate the expression of multiple 5′
HOXA genes [
24]. Recently, it was reported that HOTTIP is a negative prognostic factor in patients with liver cancer, and increased HOTTIP expression was associated with enhanced liver cancer metastasis [
25]. In addition, HOTTIP expression is linked to the formation of chemical and ultraviolet radiation-induced skin cancer [
26]. However, the underlying role and mechanism of HOTTIP in PDAC remain unknown. The focus of this study was to identify the roles that HOTTIP plays in PDAC, and to uncover the potential mechanisms by which HOTTIP contributes to disease pathogenesis.
In this study, we explored the role of HOTTIP in the regulation of proliferation, invasion, and chemoresistance of pancreatic cancer. We show that targeted silencing of HOTTIP impairs proliferation, invasion, and epithelial-mesenchymal transition ability. Moreover, for the first time, we identify an important role for HOTTIP in gemcitabine chemoresistance in pancreatic cancer cells. Furthermore, we demonstrate that HOXA13, which is located in physical contiguity with HOTTIP, is a significant target of HOTTIP, and is involved in the progression of PDAC.
Methods
Cell culture
The human pancreatic cancer cell lines, PANC-1, MIA PaCa-2, Capan-2, SW1990, and BxPC-3, were purchased from the American Type Culture Collection and grown in complete growth medium as recommended by the manufacturer, supplemented with 10% FBS and 1% penicillin/streptomycin. HPDE6 cells (immortalized human pancreatic ductal epithelial cells) were obtained from Dr. SN Zhang (Sun Yat-Sen University, Guangdong, China). All cells were cultured in a humidified 5% CO2 incubator at 37°C.
Microarray analysis
Transcriptomic analysis was performed using Arraystar human lncRNA microarrays, V3 (Agilent,Santa Clara, USA), which target 27958 Entrez protein-coding genes and 7419 lncRNAs. Total RNA was extracted and mRNA was purified using the mRNA-ONLY™ Eukaryotic mRNA Isolation Kit (Epicentre). Total RNA was fragmented, labeled (One-Color, Cy3, Agilent), purified, and hybridized with probes in Hybridization Chamber gasket slides (Agilent). The slides were then washed and scanned with an Agilent Microarray Scanner. The raw data were extracted with Agilent Feature Extraction software (Agilent). This software uses the robust multi-array average algorithm to adjust the background signals. Normalized data were obtained after performing the quantile method of intra-microarray normalization and the median method of baseline transformation between the microarrays. Differentially expressed genes with a raw expression level of >400 in more than 4 out of the 12 samples used for profiling were extracted and ordered by p-value. Genes with the highest top 10 p-values were selected for validation. The microarray platform and data were submitted to the Gene Expression Omnibus public database at the National Center for Biotechnology Information (accession number: GSE61166,
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse61166).
RNA isolation and quantitative real-time Reverse Transcription-PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, San Diego, CA, USA) according to the manufacturer’s instructions. qRT-PCR was performed for HOTTIP, HOXA13, and EMT markers (E-cadherin, Vimentin, and Snai1), with GAPDH as an internal control. RNA was extracted from frozen pancreatic cancer tissues and their corresponding non-neoplastic tissues using TRIzol reagent (Invitrogen) and qRT-PCR was performed for HOTTIP and HOXA13 mRNA using β-actin as an internal control. Total RNA was then converted to cDNA by reverse transcription using oligodT primers and SuperScript II reverse transcriptase (Invitrogen). For qRT-PCR, three replicates of each sample were amplified in a 20-μL reaction mixture containing SYBR Green reaction mix (Qiagen,Germany) and 0.5 mM of primer, and analyzed using a Roche Light-Cycler (Roche, Basel, Switzerland). The relative gene expression in cells was determined using the comparative delta-delta CT method (2-∆∆Ct) and the fold change in gene expression of tissues was calculated using the standard ∆∆CT method.
HOTTIP and HOXA13 knockdown
The following HOTTIP shRNA and scrambled control shRNA were inserted into the pLVX-tdTomato-Puro lentiviral vector (Open Biosystems, Rockford, IL ). HOTTIP shRNA forward, 5′ -GATCCGCTGCTTTAGAGCCACATATTCAAGAGATATGTGGCTCTAAAGCAGCTTTTTTCTCGAGG-3′ and reverse, 5′-AATTCCTCGAGAAAAAAGCTGCTTTAGAGCCACATATCTCTTGAATATGTGGCTCTAAAGCAGCG-3′. Scrambled control shRNA, forward, 5′-CCGGTTTCTCCGAACGTGTCACGTCTCGAGACGTGACACGTTCGGAGAATTTTTG- 3′ and reverse, 5′ -AATTCAAAAAGTTCTCCGAACGTGTCACGTCTCGAGACGTGACACGTTCGGAGAA- 3′.
shRNA lentivirus was used to generate stable HOTTIP-knockdown cells. Lentiviral particles were produced by transfecting 239 T cells. Viral supernatants were collected 72 h after transfection, and particles were concentrated using a LentiX™ Concentrator overnight at 4°C (Clontech, Mountain View, CA, USA), and aliquots were stored at −80°C. Viral titers of concentrated particles were 1.1 × 108 TU/mL. SW1990 and MIA PaCa-2 cells (5 × 105 cells/well ) were seeded in six-well culture plates and maintained in DMEM with 10% FBS for 24 h prior to infection. For screening, puromycin ( 10 μg/mL ) was added to the medium containing HOTTIP knockdown cells 72 h after infection.
The medium was then replaced every 2 days for 2–3 weeks.
SW1990 and MIA PaCa-2 cells were transfected with siRNAs targeting HOXA13 mRNA (# SIC002-1NMOL, Sigma Aldrich, St Louis, MO, USA), siHOXA13I sense: 5′-AAUGUAUUUGUGCACCU GCUdTdT-′3/antisense: 3′-dTdTUUACAUAAACACGUGGA-5′; siHOXA13II sense: 5′/5fam/-CCG UCAUGUUUCUCUCUACGAdTdT-3′/antisense: 3′-dTdTGGCAGUACAAAGAGAUGCU-5′) and an off-target negative control (# SIC007MSDS, Sigma Aldrich), using Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY, USA).
Cell growth and cell-cycle assays
For cell growth assay, SW1990 or MIA PaCa-2 cells with HOTTIP or HOXA13 knockdown were seeded in 96-well plates (1 × 103 cells per well) and pre-incubated at 37°C, 5% CO2, in a humidified atmosphere for 0, 24, 48 or 96 h. Counting Kit-8 kit (CCK-8) solution (10 μL, Dojindo Molecular Technologies, Kyushu, Japan) was then added to each well and the plate was incubated for 4 h at 37°C, 5% CO2, in a humidified atmosphere. The absorbance was measured at 450 nm using a microplate reader.
For cell-cycle analysis, SW1990 or MIA PaCa-2 cells (5 × 104 cells) with HOTTIP knockdown were collected and washed three times with PBS. Cells were then incubated in propidium iodide (PI) staining solution (RNase A 100 ug/ml and PI 500 ug/ml) for 30 min at 4°C, and cells were analyzed by flow cytometry.
Boyden chamber cell invasion
Invasion assays were performed using the BD Biocoat Matrigel Invasion Chamber (8 μm; BD Biosciences, San Jose, CA, USA) following the manufacturer’s protocol. After HOTTIP or HOXA13 knockdown, 1 × 104 cells were plated in the upper chamber. The bottom chamber contained medium with 10% FBS to stimulate invasion. After 48 h, the bottom chamber insert was stained with 0.1% crystal violet, and cells were counted by photographing the membrane using a microscope and a × 20 objective lens. Each assay was conducted at least three times.
Western blot analysis
Cells were washed in PBS and lysed with RIPA buffer (Invitrogen), and a bicinchoninic acid protein assay kit (Pierce, Rockford, IL, USA) was used to calculate the protein concentration of each sample. Equivalent amounts of proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes for immunoblotting. The membranes were blocked in 5% fat-free milk for 2 h at room temperature, washed three times, then incubated with the following primary antibodies: rabbit anti-human HOXA13 antibody (1:500, #ab26084, Abcam, Cambridge, MA, USA), rabbit anti-human E-cadherin (1:1000, #ab40772, Abcam), rabbit anti-human Vimentin (1:1000; #ab92547, Abcam), rabbit anti-human Snai1 (1:1000, #ab180714, Abcam), and rabbit anti-human GAPDH antibody (1:1000, #ab18162, Abcam). GAPDH was used as a loading control. Horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology, Boston, USA) and an ECL chemiluminescence kit (Pierce) were used to detect bound antibody.
Immunofluorescence (IF) analysis
Following introduction of SW1990 cells with shRNA or siRNA, cells were cultured to confluency on uncoated glass cover slips for 24 h, and fixed in 4% paraformaldehyde at room temperature for 15 min. After washing with PBS, the adherent cell monolayer was permeablilized with 0.1% Triton X-100 in PBS and blocked for 1 h with 10% normal goat or donkey serum in 1% BSA/PBS, followed by overnight incubation at 4°C with primary antibodies: rabbit anti-human E-cadherin (1:100, #ab40772, Abcam), rabbit anti-human Vimentin (1:100; #ab92547, Abcam), rabbit anti-human Snai1 (1:100, #ab180714, Abcam), rabbit anti-human HOXA13 antibody (1:100, #sc-133669, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA). After washing with PBS, cells were incubated with the Alexa 488-conjugated secondary antibody (#A20181, Molecular Probes, Leiden, The Netherlands) for 1 h. Cells were then washed three times with PBS and mounted in Vectashield containing DAPI (#ab104139, Abcam). The slides were analyzed using a confocal laser scan microscope.
In vitro chemosensitivity assay
SW1990 cells transduceded with shHOTTIP or control shRNA were seeded (5 × 103/well) in 96-well plates. After incubation for 24 h, varying concentrations of gemcitabine (Lilly, Indianapolis, IN, USA) were added to the cells. After 72 h incubation in a humidified atmosphere containing 5% CO2, 10 μL CCK-8 reagent was added to each well and cells were incubated for 4 h. The absorbance of each well was determined using an ELISA reader (Wellscan MK3; Labsystems Dragon, Finland) at a wavelength of 450 nm.
For colony formation, SW1990 cells transduced with shHOTTIP or control shRNA were seeded (500 cells/well) in six-well plates overnight and gemcitabine (10 μM) or PBS (100 μL) was added to the cultured cells on the second day. After 14 days, the culture medium was removed, and cells were briefly rinsed with PBS. The cells were then fixed with 4% paraformaldehyde and stained with 0.1% crystal violet, and colonies were counted by visual inspection.
In vivo chemosensitivity assays
All experiments involving animals were conducted according to the institutional guidelines of Guangdong Province and were approved by the institutional guidelines of Guangdong Province and by the Use Committee for Animal Care. BALB/c nude mice (4–6 weeks old) were randomly separated into the following groups (n = 4 mice per group): (a) SW1990-shcontrol, PBS; (b) SW1990-shHOTTIP, PBS; (c) SW1990-shcontrol, gemcitabine; (d) SW1990-shHOTTIP, gemcitabine. Each mouse was inoculated subcutaneously in the dorsal flank with SW1990 cells (3 × 106 cells/mouse) stably transduced with shHOTTIP or control shRNA. When the xenografts reached a mean size of 0.1–0.15 cm2 on the 5th day after cell injection, the mice received gemcitabine (120 mg/kg) or PBS (100 μL) via intraperitoneal (i.p.) injection once every 3 days. All groups were treated five times. The tumors were measured every 3–4 days, and tumor volume was calculated using the following formula: volume = (L × W2)/2, where L and W are the longest and shortest diameters, respectively. The mice were sacrificed when the average L of any group reached approximately 1 cm.
Immunohistochemistry staining and scoring
Paraffin-embedded samples of primary carcinomas were stained for HOXA13. Sections were deparaffinized in xylene and rehydrated in a graded series of ethanol, followed by heat-induced epitope retrieval in citrate buffer (pH = 6.0). Antigen retrieval was performed in 10 mmol/L citrate buffer (pH = 6.0) in a microwave oven for 15 min. The activity of endogenous peroxidases was blocked by the addition of 3% hydrogen peroxide for 10 min at room temperature. Rabbit HOXA13 antibody (#ab26084, Abcam, 1:100) was applied overnight at 4°C, and after washing three times in PBS, sections were immunostained with a goat anti-rabbit secondary antibody (#191866, Abcam, 0.2 ug/ml) for 1 h at 37°C. The slides were incubated with streptavidin-HRP conjugate complex for 45 min at 37°C. After rinsing three times in PBS, the sections were developed with 3,3′-diaminobenzidine. Sections were counterstained with hematoxylin. Sections of skin tissues known to stain positive for HOXA13 were used as positive controls, and normal goat serum and PBS substituting the primary antibody were used as negative controls.
For evaluation and grading of HOXA13 staining results, a scoring criterion previously described by Ohara et al. [
27] was used. Briefly, the staining intensity of HOXA13 was graded on a scale of 0–3 (0, none; 1, weak; 2, intermediate; and 3, strong). HOXA13 expression was assessed according to the percentage of staining as follows: 0 points for no staining; 1 point for <25% staining; 2 points for 26–50% staining; 3 points for 51–75% staining; and 4 points for 76–100% staining. The total score was calculated as the product of the scores for the intensity and positive rate of staining. Staining was assessed by two pathologists according to the scoring criteria. Cases with discrepancies were jointly reevaluated until a consensus was reached.
Patient samples
All samples were obtained from patients undergoing resection of the pancreas at the Sun Yat-Sen Memorial Hospital between 2009 and 2014. Informed consent was obtained from all patients before sample collection. All patients had a clear histological diagnosis. Patient specimens and related clinicopathological data, including complete follow-up, were obtained from the Institute of Pathology and from the Department of Pancreaticobiliary, Sun Yat-Sen Memorial Hospital. All patients in this study met the following criteria: PDAC diagnosis verified by pathological examination, paraffin-embedded tissues were well stored and qualified for serial section, the corresponding tumor tissues and the paired non-tumor tissues were stored in liquid nitrogen immediately following surgical removal, no anticancer treatments given before biopsy collection, and available exhaustive clinicopathologic and follow-up data.
Statistical analysis
Statistical analyses were performed using SPSS Statistics 16.0 (IBM Chicago, IL, USA). The chi-square test (X2 test), Fisher’s exact test for non-parametric variables, and Student’s t test for parametric variables were used (two-tailed). Differences in patient survival were assessed using the Kaplan–Meier method and analyzed using the log-rank test in a univariate analysis. All tests were two-sided, and a p < 0.05 was considered statistically significant.
Discussion
The prognosis of PDAC is extremely poor, therefore, understanding the mechanisms underlying PDAC pathogenesis may help yield novel biomarkers for early detection and treatment [
8]. Recent studies have shown that dysregulated expression of lncRNAs in solid cancers reflect disease progression and may independently predict patient outcome [
22,
23]. In the present study, we demonstrate that a lncRNA HOXA transcript at the distal tip (HOTTIP, is associated with PDAC tumor progression and disease outcome.
Rinn and coworkers have identified up to 3000 lncRNAs [
28,
29], and biological characterization of these demonstrates that lncRNAs are master regulators of embryonic pluripotency, differentiation, and body axis patterning. In addition, lncRNAs have been shown to promote developmental transitions and regulate histone modifications and hence influence the epigenetic programs of the transcriptome [
30,
31]. Of note, lncRNAs may also play roles as drivers of tumor suppression or exert oncogenic functions in a wide variety of cancer types, by sustaining tumor cell proliferation, evading growth suppressors, enabling replicative immortality, inducing angiogenesis, and promoting invasion and metastasis [
32-
34].
To date, many transcribed lncRNAs have been implicated in gene silencing [
35,
36], but the potential roles of lncRNAs in gene activation are much less understood [
28,
37]. Recently, a lncRNA named HOTTIP, which resides at the 5′ tip of the
HOXA locus and coordinates the activation of multiple 5′
HOXA genes
in vivo [
24], has been identified as one of 231 lncRNAs associated with the human
HOX loci [
28]. This lncRNA directly binds the adaptor protein WDR5 and targets WDR5/MLL complexes across
HOXA, thus driving histone H3 lysine 4 trimethylation and gene transcription [
24]. Furthermore, expression of HOTTIP has been identified as a negative prognostic factor in hepatocellular carcinoma patients [
25]; however, the functional role of HOTTIP in cancer progression remains unknown. This present study offers the first insight into the effect of HOTTIP on malignant cell behavior. Our results demonstrate that HOTTIP, which is overexpressed in human pancreatic cancer tissues and cells compared with non-tumoral tissues and cell lines, enhances pancreatic cell proliferation and invasion as well as EMT. In addition, we show that targeted silencing of HOTTIP potentiates the antitumor effects of gemcitabine both
in vitro and
in vivo.
The
HOX family of homeobox genes encodes transcriptional regulators that are expressed during development in regionalized domains along the main body axis (limb, lung, gut, and lower genitourinary tract), where they regulate cell proliferation and differentiation [
38]. Additionally,
HOX genes represent the most repeat-poor regions within the human genome and display a unique gene network organization (four chromosomal loci: A, B, C, and D). The
HOXA locus consists of a cluster of 11
HOX genes with a graded expression pattern along body appendages from proximal (close to the main body) to distal (appendage tip) [
39,
40]. Among the
HOXA genes,
HOXA13, which is a marker of gut primordial posteriorization during development [
41], has been shown to play a crucial role in tumorigenesis of the liver and bladder and in esophageal cancer [
42-
44]. In the present study,
HOXA13 was the most significantly inhibited gene within the
HOXA locus following depletion of HOTTIP in pancreatic cancer cells. Located in physical continuity (chr7p 15.2) with the
HOXA13 gene [
24], HOTTIP is expressed from development to adulthood in lumbosacral anatomc regions, explaining this regulatory relationship. Our observation is also in agreement with previously published data conducted in fibroblasts from a distal anatomic site (foreskin) [
24]. Moreover, we found that HOTTIP and HOXA13 expression was strongly positively correlated in 90 PDAC tissues and in their corresponding adjacent nonneoplastic tissues. In addition, siRNA-mediated HOXA13-knockdown inhibited the proliferation, invasion, and EMT of PDAC cells, which was consistent with the functional changes that occurred after silencing the expression of HOTTIP in PDAC cells. In addition to the HOTTIP-targeted regulation of HOXA13 expression, we also observed reduced HOTTIP levels upon siRNA-mediated knockdown of HOXA13 in two different pancreatic cancer cell lines. Targeted inhibition of HOXA13 in SW1990 cells led to a 77% reduction in the mRNA level of HOXA13, and HOTTIP expression was also reduced by 48.2%. Similarly, in MIA PaCa-2 cells, HOXA13 levels were reduced to 29.3%, with a concomitant 39.6% reduction in HOTTIP levels. Our data are consistent with a pioneering study demonstrating that decreased expression of HOXA13 led to a clear reduction of HOTTIP expression in liver cancer-derived cell lines [
26]. Thus, our work confirms that the regulatory loop between HOTTIP and its target, HOXA13, is also preserved during pancreatic cancer tumorigenesis. Taken together, our results support a mechanism whereby the HOTTIP/HOXA13 axis plays a critical role in PDAC tumorigenesis. Analysis of the relationship between HOXA13 expression in paraffin-embedded PDAC samples and clinicopathological data indicates that patients with high HOXA13 expression exhibit increased lymph node metastasis, poor histological differentiation, and decreased overall survival (Table
1, Figure
5). Hence, our findings are clinically and functionally relevant to the progression of human PDAC.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RFC and ZQF conceived and performed the experiments, analyzed and interpreted the data, and drafted the manuscript. XHZ and ZL conceived the experiments, analyzed and interpreted data, and wrote the manuscript. YZ, ZQF, QBZ, HLY, YML, JLZ, YXW, YDS, WCG, SYZ, BXZ, HMC, and WZL participated in the experiments and helped analyzed data. All authors read and approved the final manuscript.
This is the first study to confirm the association between the HOTTIP/HOXA13 axis and pancreatic cancer. Our results indicate that the HOTTIP/HOXA13 axis, which underlies the biology and mediates chemoresistance of pancreatic cancer, is a potential biomarker and therapeutic target in pancreatic cancer.